{
    "nct_id": "NCT05397496",
    "official_title": "A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies",
    "inclusion_criteria": "* Signed informed consent must be obtained prior to participation in the study.\n* Male or female patients ≥18 years of age at the date of signing the informed consent form\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2\n\nNHL patient population\n\n* Refractory or relapsed B-NHL\n* Must have relapsed after or failed to respond to at least two prior treatment therapies including an αCD20 monoclonal antibody containing chemotherapy combination regimen\n* Must have at least one bi-dimensionally measurable nodal lesion or one bi-dimensionally measurable extranodal lesion, as measured on positron emission tomography-computed tomography (PET/CT) scan\n\nALL patient population\n\n* Refractory or relapsed CD19-positive B-ALL\n* Morphologic disease in the bone marrow (≥ 5% blasts)\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* History of severe hypersensitivity to any ingredient of the study treatment or its excipients\n* Contraindication to tocilizumab\n* History of ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection\n* Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type\n* Active central nervous system (CNS) involvement by malignancy or presence of symptomatic CNS metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within the 2 weeks prior to the start of study treatment\n* Active, known or suspected autoimmune disease other than patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur\n* Patients receiving systemic treatment with any immunosuppressive medication\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}